Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioPharma CreditLSE:BPCR +0.21%52 5-Year Yield-on-Cost % is 7.29 as of Jul. 14, 2026, which is 0% below its 10-year median of 7.31. GuruFocus rates LSE:BPCR with a GF Score™ of 52/100 and a GF Value™ of $0.96 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,114 Asset Management companies, BioPharma Credit ranks better than 56.55% on this metric.
BioPharma Credit's yield on cost for the quarter that ended in Dec. 2025 was 7.29.
The historical rank and industry rank for BioPharma Credit's 5-Year Yield-on-Cost % or its related term are showing as below:
LSE:BPCR'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 5.42 Med: 7.31 Max: 8.58
Current: 7.29
During the past 9 years, BioPharma Credit's highest Yield on Cost was 8.58. The lowest was 5.42. And the median was 7.31.
LSE:BPCR's 5-Year Yield-on-Cost % is ranked better than 56.55% of 1114
companies
in the Asset Management industry
Industry Median: 6.45
vs LSE:BPCR: 7.29
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
BioPharma Credit 5-Year Yield-on-Cost % Related Terms
LSE:BPCR vs BLK, BX, KKR: 5-Year Yield-on-Cost % Comparison
For the Asset Management subindustry, BioPharma Credit's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit 5-Year Yield-on-Cost % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
BioPharma Credit (LSE:BPCR) has a 5-Year Yield-on-Cost % of 7.29 as of Jul. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on BioPharma Credit and its competitors. This is near median its historical median of 7.31. Over the past decade, BioPharma Credit's 5-Year Yield-on-Cost % has ranged from 5.42 to 8.58. According to the industry distribution chart, BioPharma Credit ranks #484 out of 1114 companies in the Asset Management industry, placing it in the top 43.4%.
Is BioPharma Credit's 5-Year Yield-on-Cost % too high?
BioPharma Credit's current 5-Year Yield-on-Cost % of 7.29 is near median its 10-year median of 7.31. Over the past 10 years, this metric has ranged from a low of 5.42 to a high of 8.58. The Asset Management industry median 5-Year Yield-on-Cost % is 6.45. BioPharma Credit's value of 7.29 is 13% above this industry median. Based on the distribution chart, BioPharma Credit ranks #484 out of 1114 companies in the Asset Management industry, which is above the industry midpoint. Overall, BioPharma Credit has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's 5-Year Yield-on-Cost % compare to BLK and BX?
According to the Asset Management industry distribution chart, BioPharma Credit ranks #484 out of 1114 companies for 5-Year Yield-on-Cost %. This puts BioPharma Credit in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 6.45. BioPharma Credit's value of 7.29 is 13% above this benchmark. Historically, BioPharma Credit's own 5-Year Yield-on-Cost % has ranged from 5.42 to 8.58 over the past decade. While the company's 10-year median is 7.31 vs. the industry median of 6.45, BioPharma Credit has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for an Asset Management company?
The median 5-Year Yield-on-Cost % among Asset Management companies is 6.45, based on 1,114 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPharma Credit's current 5-Year Yield-on-Cost % of 7.29 is 13% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on BioPharma Credit and its competitors. For the Asset Management industry, the median 5-Year Yield-on-Cost % is 6.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPharma Credit's current 5-Year Yield-on-Cost % is 7.29, which is near median its own 10-year median of 7.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.96 — trading 0.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 7.29, which is near median its 10-year median of 7.31 and 13% above the Asset Management industry median of 6.45. BioPharma Credit's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current 5-Year Yield-on-Cost % is 7.29 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be overvalued.
The current stock price of $0.96 is trading 0.2% above its estimated GF Value™ of $0.96.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
5-Year Yield-on-Cost %: 7.29 (near median its 10-year median of 7.31)
GF Value™: $0.96 vs. price of $0.96 (0.2% above fair value)
Industry Position: 13% above the Asset Management median (#484 of 1114)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
52GF Score
Get the complete analysis for LSE:BPCR
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
